VEREGEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEREGEN (VEREGEN).
Veregen (sinecatechins) is a topical botanical drug product containing a defined mixture of catechins from green tea leaves. Its exact mechanism of action is unknown, but it is thought to involve immunomodulatory and antiviral activities, including inhibition of cellular proliferation and induction of apoptosis in HPV-infected cells.
| Metabolism | Not extensively metabolized; based on minimal systemic absorption after topical application, metabolism is not fully characterized. |
| Excretion | Following topical application, systemic absorption of sinecatechins is minimal. Unabsorbed drug is eliminated primarily in feces. Renal excretion of absorbed drug is negligible (<1%). |
| Half-life | The terminal elimination half-life cannot be accurately determined due to minimal systemic absorption; however, based on limited systemic exposure, the half-life is estimated to be less than 2 hours. |
| Protein binding | Due to minimal systemic absorption, protein binding data are not clinically relevant. In vitro studies suggest binding to albumin and other plasma proteins is >90%. |
| Volume of Distribution | Vd cannot be reliably calculated due to negligible systemic absorption; estimated to be low (<0.1 L/kg) based on physicochemical properties. |
| Bioavailability | Bioavailability is negligible (<0.1%) after topical application; systemic absorption is minimal. |
| Onset of Action | Clinical effect (clearance of external genital and perianal warts) typically observed after 4-8 weeks of thrice-daily application. |
| Duration of Action | Duration of action is not well-defined; treatment continues until complete clearance of warts, usually up to 16 weeks. Recurrence rates are variable. |
| Molecular Weight | 282.29 |
Topical application of 15% ointment to external genital and perianal warts three times daily (every 8 hours) for up to 16 weeks.
| Dosage form | OINTMENT |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No dosage adjustment required for any degree of hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years of age. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to higher frequency of concomitant conditions and medications. |
| 1st trimester | Category C; no adequate human studies; animal studies show risk. Avoid in first trimester unless benefit outweighs risk. |
| 2nd trimester | Category C; limited data; use only if clearly needed. |
| 3rd trimester | Category C; near term, avoid due to potential for systemic absorption and effects on fetal skin. |
Clinical note
Comprehensive clinical and safety monograph for VEREGEN (VEREGEN).
| Placental transfer | Likely low molecular weight and lipophilic nature suggest potential crossing; no formal studies. |
| Breastfeeding | Not known if excreted in human milk; caution due to potential for skin irritation and systemic absorption in infant. Avoid applying to breast area. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to sinecatechins or any componentApplication to open wounds or mucous membranes
| Precautions | Not for use on mucous membranes (e.g., vaginal, cervical, oral, or urethral warts), Avoid application to open wounds or inflamed skin, Sexual contact should be avoided while ointment is on the skin, May weaken condoms and diaphragms; avoid concurrent use during treatment, Use in patients with compromised skin immunity has not been studied |
| Food/Dietary | No known food interactions. Avoid concomitant use of other topical products on the same area unless directed by a healthcare provider. |
Loading safety data…
| L3 (Moderate Safety) |
| Teratogenic Risk | Veregen (sinecatechins) is a botanical drug product indicated for topical treatment of external genital and perianal warts. Systemic absorption is minimal following topical application. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with sinecatechins. Based on negligible systemic absorption, the risk of fetal harm is considered low, but it should be used during pregnancy only if clearly needed. |
| Fetal Monitoring | No specific maternal or fetal monitoring is required beyond usual prenatal care. If applied to genital area during pregnancy, observe for local reactions. Systemic effects are unlikely due to minimal absorption. |
| Fertility Effects | No studies have been conducted on the effects of sinecatechins on fertility. Based on the minimal systemic absorption, effects on fertility are unlikely. |
| Clinical Pearls |
| Veregen (sinecatechins) is a topical botanical drug product containing catechins from green tea leaves. It is indicated for the treatment of external genital and perianal warts (condylomata acuminata). Apply a 0.5 cm strand of ointment to each wart three times daily. Do not wash treated area for at least 10 minutes after application. Avoid use on open wounds, mucous membranes, or in immunocompromised patients. Efficacy may take up to 16 weeks; if no improvement, consider alternative therapy. |
| Patient Advice | Apply a thin layer of ointment (about 0.5 cm strand) to each wart three times daily. · Do not wash the treated area for at least 10 minutes after application. · Avoid sexual contact while ointment is on the skin. · Do not use on open wounds, broken skin, or inside the vagina or anus. · Common side effects include local skin reactions like redness, irritation, and pain. · If severe skin reactions occur, stop use and consult healthcare provider. · Treatment duration can be up to 16 weeks; if warts do not improve, see your doctor. |